Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond

被引：4
作者：
Keiffer, Gina [1 ]
Aderhold, Kimberly L. [1 ]
Palmisiano, Neil D. [1 ]
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
来源：
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词：
acute myeloid leukemia; FLT3; midostaurin; gilteritinib; first line; ACUTE MYELOID-LEUKEMIA; FLT3; CHEMOTHERAPY; MUTATIONS; CYTOGENETICS; RESISTANCE; INHIBITOR; PKC412;
D O I：
10.3389/fonc.2020.562219
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 23 条
[1]   The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib [J].
Albers, C. ;
Leischner, H. ;
Verbeek, M. ;
Yu, C. ;
Illert, A. L. ;
Peschel, C. ;
von Bubnoff, N. ;
Duyster, J. .
LEUKEMIA, 2013, 27 (06) :1416-1418
[2]   Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia [J].
Altman, Jessica K. ;
Foran, James M. ;
Pratz, Keith W. ;
Trone, Denise ;
Cortes, Jorge E. ;
Tallman, Martin S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) :213-221
[3]   Potential targeting of FLT3 acute myeloid leukemia [J].
Ambinder, Alexander J. ;
Levis, Mark .
HAEMATOLOGICA, 2021, 106 (03) :671-681
[4]   FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions [J].
Antar, Ahmad I. ;
Otrock, Zaher K. ;
Jabbour, Elias ;
Mohty, Mohamad ;
Bazarbachi, Ali .
LEUKEMIA, 2020, 34 (03) :682-696
[5]   Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].
Doehner, Hartmut ;
Estey, Elihu ;
Grimwade, David ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Dombret, Herve ;
Ebert, Benjamin L. ;
Fenaux, Pierre ;
Larson, Richard A. ;
Levine, Ross L. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel ;
Sierra, Jorge ;
Tallman, Martin S. ;
Tien, Hwei-Fang ;
Wei, Andrew H. ;
Lowenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2017, 129 (04) :424-447
[6]   Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 [J].
Fischer, Thomas ;
Stone, Richard M. ;
DeAngelo, Daniel J. ;
Galinsky, Ilene ;
Estey, Elihu ;
Lanza, Carlo ;
Fox, Edward ;
Ehninger, Gerhard ;
Feldman, Eric J. ;
Schiller, Gary J. ;
Klimek, Virginia M. ;
Nimer, Stephen D. ;
Gilliland, D. Gary ;
Dutreix, Catherine ;
Huntsman-Labed, Alice ;
Virkus, Jodi ;
Giles, Francis J. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4339-4345
[7]   Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].
Fröhling, S ;
Schlenk, RF ;
Breitruck, J ;
Benner, A ;
Kreitmeier, S ;
Tobis, K ;
Döhner, H ;
Döhner, K .
BLOOD, 2002, 100 (13) :4372-4380
[8]   Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia [J].
Jan, Max ;
Snyder, Thomas M. ;
Corces-Zimmerman, M. Ryan ;
Vyas, Paresh ;
Weissman, Irving L. ;
Quake, Stephen R. ;
Majeti, Ravindra .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (149)
[9]   FMS-LIKE TYROSINE KINASE 3/FLT3: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS [J].
Kazi, Julhash U. ;
Ronnstrand, Lars .
PHYSIOLOGICAL REVIEWS, 2019, 99 (03) :1433-1466
[10]   The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials [J].
Kottaridis, PD ;
Gale, RE ;
Frew, ME ;
Harrison, G ;
Langabeer, SE ;
Belton, AA ;
Walker, H ;
Wheatley, K ;
Bowen, DT ;
Burnett, AK ;
Goldstone, AH ;
Linch, DC .
BLOOD, 2001, 98 (06) :1752-1759
123